Verastem’s Promising Phase 3 Study in Ovarian Cancer: A Potential Game-Changer?

Verastem Inc ((VSTM)) announced an update on their ongoing clinical study.

Verastem Inc. is conducting a Phase 3 study titled A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator’s Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301). The study aims to evaluate the safety and efficacy of the combination of avutometinib and defactinib compared to standard treatments in patients with recurrent LGSOC who have previously undergone platinum-based therapy. This study is significant as it explores new treatment avenues for a challenging cancer type.

The interventions being tested are avutometinib and defactinib, both kinase inhibitors designed to block cancer cell growth. These investigational drugs are administered orally and are not yet FDA-approved.

The study employs a randomized, open-label, crossover design with no masking, focusing on treatment as the primary purpose. Participants will either receive the investigational combination or one of four standard treatments, with an option to switch to the investigational drugs if disease progression occurs.

The study began on March 18, 2024, with the last update submitted on August 7, 2025. These dates are crucial as they indicate the study’s progress and current status in the recruitment phase.

This clinical update could positively impact Verastem’s stock performance by showcasing potential advancements in cancer treatment, potentially boosting investor confidence. The study’s outcome may also influence the competitive landscape in the oncology sector.

The study is ongoing, with further details available on the ClinicalTrials portal.